PL EN
 
1/2022 vol. 48
Stats
Get citation
Level of depression and occurrence of cognitive changes in patients with multiple myeloma - a preliminary report
Magdalena Bury-Kamińska 1
,
 
Aneta Szudy-Szczyrek 2
,
 
Monika Kozłowiec 2
,
 
Olga Jankowska-Łęcka 2
,
 
Aleksandra Nowaczyńska 2
,
 
Marek Hus 2
 
 
 
More details
Hide details
1
Instytut Psychologii, Uniwersytet Marii Curie-Skłodowskiej w Lublinie
 
2
Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Uniwersytet Medyczny w Lublinie
 
 
Submission date: 2021-10-29
 
 
Final revision date: 2022-05-20
 
 
Acceptance date: 2022-05-26
 
 
Publication date: 2022-07-31
 
 
Corresponding author
Magdalena Bury-Kamińska   

Instytut Psychologii, Uniwersytet Marii Curie-Skłodowskiej w Lublinie
 
 
JoMS 2022;48(1):461-475
DOI: https://doi.org/10.13166/jms/150467
 
 
Article (PDF)
References (32)
 
KEYWORDS
depression
cancer
multiple myeloma
cognitive dysfunctions
chemobrain
 
TOPICS
Psychology
_Other
 
ABSTRACT
Objectives:
The aim of the article is to study the changes in the level of cognitive and affective functioning in patients with multiple myeloma undergoing chemotherapy.

Material and methods:
Montreal Cognitive Assessment scale (MoCA) - screening method - was used to determine the general cognitive state of patients. The general level of depression and its characteristic symptoms were determined with the use of Depression Measurement Questionnaire.

Results:
Gathering first initial results of author’s own research – increasing the research sample could indicate an improved cognitive functioning in patients with multiple myeloma during chemotherapeutic treatment. Moreover, the research demonstrates a decrease in depression symptoms, i.e., self-blame and anxiety states, during chemotherapy.

Conclusions:
The study requires further research owing to a small group of research participants (n=21), the presence of research data at the level of statistical tendency, and a need for a comparison with a group of healthy people (without a cancer diagnosis).

 
REFERENCES (32)
1.
Bender, C.M., Sereika, S.M., Berga, S.L. i in. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. „Psycho‐Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer”, No. 15(5), s. 422–430.
Google Scholar
 
 
2.
Bury, M., Borkowska, A.R., Daniluk, B. (2014). Impact of chemotherapy on memory, attention and executive functions depending on the stages of treatment and the level of depression in female patients with cancer. „Acta Neuropsychologica”, No. 12(4).
Google Scholar
 
 
3.
Castellino, S.M., Ullrich, N.J., Whelen, M.J. i in. (2014). Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. „Journal of the National Cancer Institute”, 106 (8), 186.
Google Scholar
 
 
4.
Chojnacka-Szawłowska, G. (2012). Psychologiczne aspekty przewlekłych chorób somatycznych. Warszawa, Wydawnictwo Vizja Press & IT.
Google Scholar
 
 
5.
Cull, A., Hay, C., Love, S.B. i in. (1996). What do cancer patients mean when they complain of concentration and memory problems? „British Journal of Cancer”, No. 74(10), s. 1674.
Google Scholar
 
 
6.
de Walden-Gałuszko, K. (2014). Psychoonkologia w praktyce klinicznej. Warszawa: Wydawnictwo Lekarskie PZWL.
Google Scholar
 
 
7.
Debess, J., Riis, J.Ø., Engebjerg, M.C. i in. (2010). Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. „Breast Cancer Research and Treatment”, No. 121(1), s. 91–100.
Google Scholar
 
 
8.
Fallowfield, L. (1990). What is quality of life, London, Souvenir, s. 54–57.
Google Scholar
 
 
9.
Ferguson, R.J., McDonald, B.C., Saykin, A.J. i in. (2007). Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. „Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology”, No. 25(25), s. 3866–3870.
Google Scholar
 
 
10.
Hermelink K. (2011). Chemobrain? Zaburzenia poznawcze po chemioterapii. W: M. Dorfmüller, H. Dietzfelbinger (red.). Psychoonkologia. Diagnostyka – Metody terapeutyczne. Wrocław, Wydawnictwo Elsevier Urban & Partner, s. 71–73.
Google Scholar
 
 
11.
Hermelink, K. i in. (2010). Two different sides of ‘chemobrain’: determinants and nondeterminants of self‐perceived cognitive dysfunction in a prospective, randomized, multicenter study. „Psycho‐Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer”, No. 19(12), s. 1321–1328.
Google Scholar
 
 
12.
Jacobs, S.R. i in. (2007). Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. „Cancer”, No. 110(7), s. 1560–1567.
Google Scholar
 
 
13.
Jansen, C.E., Cooper, B.A., Dodd, M.J. (2011). A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients, „Supportive Care in Cancer”, No. 19(10), s. 1647–1656.
Google Scholar
 
 
14.
Jean-Pierre, P. (2010). Management of cancer-related cognitive dysfunction – conceptualization challenges and implications for clinical research and practice. „US Oncology”, No. 6(9).
Google Scholar
 
 
15.
Jones, D. i in. (2013). Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. „Cancer”, No. 119(23), s. 4188–4195.
Google Scholar
 
 
16.
Khalil, R.B. (2021). “Emotional Chemobrain”: A new concept for chemotherapy adverse drug effect?. „L’Encéphale”, No. 47(6), s. 613-615..
Google Scholar
 
 
17.
Łojek, E., Stańczak, J., Wójcik, A. (2015). Kwestionariusz do Pomiaru Depresji KPD. Podręcznik. Warszawa, Pracowania Testów Psychologicznych.
Google Scholar
 
 
18.
Mehlsen, M. i in. (2009). No indications of cognitive side‐effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. „Psycho‐Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer”, No. 18(3), s. 248–257.
Google Scholar
 
 
19.
Nowicki, A., Rządkowska, B. (2005). Depresja i lęk u chorych z nowotworami złośliwymi. „Współczesna Onkologia”, No. 9(9), s. 396–403.
Google Scholar
 
 
20.
Quesnel, C., Savard, J., Ivers, H. (2009). Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. „Breast Cancer Research and Treatment”, No. 116(1), s. 113–123.
Google Scholar
 
 
21.
Rolińska, A., Furmaga, O., Kwaśniewski, W. i in. (2011). Zaburzenia psychiczne w przebiegu choroby nowotworowej. „Current Problems of Psychiatry”, No. 12(4), s. 546–549.
Google Scholar
 
 
22.
Roman, S. i in. (2019). Cognition in Multiple Myeloma Patients. „Biology of Blood and Marrow Transplantation”, No. 25(3), s. 374–375.
Google Scholar
 
 
23.
Schagen, S.B. i in. (2006). Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. „Journal of the National Cancer Institute”, No. 98(23), s. 1742–1745.
Google Scholar
 
 
24.
Schagen, S.B. i in. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. „Cancer”, No. 85(3), s. 640–650.
Google Scholar
 
 
25.
Scherling, C.S., Smith, A. (2013). Opening up the window into “chemobrain”: a neuroimaging review. „Sensors”, No. 13(3), s. 3169–3203.
Google Scholar
 
 
26.
Silverman, D.H. i in. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. „Breast Cancer Research and Treatment”, No. 103(3), s. 303–311.
Google Scholar
 
 
27.
Stępień, R., Wrońska, I. (2008). Lęk i depresja jako emocjonalne uwarunkowania możliwości funkcjonalnych kobiet po radykalnym leczeniu raka piersi. „Studia Medyczne”, nr 10, s. 31–35.
Google Scholar
 
 
28.
Talarowska, M. i in. (2011). Skala MOCA oraz MMSE w diagnozie łagodnych zaburzeń funkcji poznawczych. MOCA and MMSE in the diagnosis of Mild Cognitive Impairment. „Psychiatria i Psychoterapia”, nr 7(1), s. 13–20.
Google Scholar
 
 
29.
Tannock, I.F. i in. (2004). Cognitive impairment associated with chemotherapy for cancer: report of a workshop. „Journal of Clinical Oncology”, No. 22(11), s. 2233–2239.
Google Scholar
 
 
30.
Van Dam, F.S. i in. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. „Journal of the National Cancer Institute”, No. 90(3), s. 210–218.
Google Scholar
 
 
31.
Wefel, J.S. i in. (2004). ‘Chemobrain’in breast carcinoma? „Cancer”, No. 101(3), s. 466–475.
Google Scholar
 
 
32.
Whitney, K.A. i in. (2007). Is “chemobrain” a transient state? A prospective pilot study among persons with non-small cell lung cancer. „The Journal of Supportive Oncology”, No. 6(7), s. 313–321.
Google Scholar
 
 
Share
Send by email
RELATED ARTICLE
Validation and Psychometric Properties of the Polish Version of the Fear of COVID-19 Scale Among Adolescents
Psychological protective factors and individual functioning during the Covid-19 pandemic
Indexes
 
Keywords index
Topics index
Authors index
eISSN:2391-789X
ISSN:1734-2031
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top